Mar 28, 2025 | 50 states and territories | Alaska | Apotex | Arizona | artificially inflate and manipulate prices | AUROBINDO PHARMA USA INC. | California | Colorado | Connecticut | Conspiracy to Inflate Drug Prices | DCA | Delaware | Division of Consumer Affairs | Division of Law | Florida | generic drug manufacturer | generic prescription drugs | Georgia | Heritage Pharmaceuticals | Idaho | Illinois | Inc. | Indiana | Iowa | Kansas | Kentucky | Limit Competition | Louisiana | Maine | Maryland | Massachusetts | Michigan | Minnesota | Mississippi | Missouri | Montana | Nebraska | Nevada | New Hampshire | New Jersey | New Mexico | New York | North Carolina | North Dakota | Northern Mariana Islands | Ohio | Oklahoma | Oregon | Pennsylvania | preliminary approval for a settlement | Puerto Rico | reduce competition | Rhode Island | SANDOZ | Settlement | South Carolina | South Dakota | Tennessee | TEVA PHARMACEUTICALS USA INC. | the District of Columbia | U.S. District Court for the District of Connecticut | U.S. Virgin Islands | unreasonably restrain trade | Utah | Vermont | Virginia | Washington | West Virginia | widespread long-running conspiracies | Wisconsin | Wyoming. | Division of Consumer Affairs | Division of Law | Press Release | Protecting New Jersey Consumers | Protecting New Jersey in Court
Attorney General Matthew J. Platkin is urging consumers to check their eligibility for compensation for certain generic drug purchases as New Jersey joins 50 states and territories in seeking preliminary approval for a $39.1 million settlement with generic drug manufacturer Apotex over conspiracy to inflate prices and limit competition.
